Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clene Inc.CLNN · Entity 7166 | Director | August 13, 2026 | August 14, 2026 |
| Longeveron Inc.LGVN · Entity 7608 | Director | August 19, 2026 | August 21, 2026 |
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director | June 12, 2025 | June 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clene Inc.
Report date August 13, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| stock optionSEC Table II · derivative / convertible security · Conversion / exercise price $4.19 · Expires 2036-08-12 | Direct | 3,674 |
Reported balance
After 2026-08-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-13 · Grant · Acquired 3,674 · Balance 3,674 F1: This option was granted on August 13, 2026 as an option for 3,674 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on August 13, 2026 as an option for 3,674 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant.
Longeveron Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 36,000 |
Reported balance
After 2026-08-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-19 · Grant · Acquired 36,000 · Balance 36,000 F1: Represents the award of time-based vesting Restricted Stock Units (RSUs). F2: Includes RSUs subject to future vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of time-based vesting Restricted Stock Units (RSUs).
F2: Includes RSUs subject to future vesting.
TriSalus Life Sciences, Inc.
Report date June 12, 2025 · Filed June 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2035-06-11 | Direct | 65,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 15,000 · Balance 65,000 F1: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 22:00 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantClass A Common Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-010738 · marketforms-73829.xml · nonDerivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 F1 · shares: Represents the award of time-based vesting Restricted Stock Units (RSUs). F2 · balance_after: Includes RSUs subject to future vesting. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 19:32 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 3,674 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001437749-26-027971 · rdgdoc.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,674 Underlying: common stock · 3,674 shares Expires 2036-08-12 F1 · derivative.exercise_date: This option was granted on August 13, 2026 as an option for 3,674 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.19 per share. The options vest immediately upon grant. Read SEC document |
| May 21, 2026 Filed May 22, 2026 18:02 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 2,158 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001437749-26-018220 · rdgdoc.xml · derivative · entry 2 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,158 Underlying: common stock · 2,158 shares Expires 2036-05-20 F2 · derivative.exercise_date: This option was granted on May 21, 2026 as an option for 2,158 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest immediately upon grant. Read SEC document |
| May 21, 2026 Filed May 22, 2026 18:02 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 1,500 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001437749-26-018220 · rdgdoc.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: common stock · 1,500 shares Expires 2036-05-20 F1 · derivative.exercise_date: This option was granted on May 21, 2026 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.81 per share. The options vest in 12 equal monthly installments on the 21st day of each calendar month, beginning June 21, 2026, until such shares are fully vested. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:03 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 3,168 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001437749-26-004903 · rdgdoc.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,168 Underlying: common stock · 3,168 shares Expires 2036-02-18 F1 · derivative.exercise_date: This option was granted on February 19, 2026 as an option for 3,168 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:44 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 2,177 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001437749-25-035225 · rdgdoc.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,177 Underlying: common stock · 2,177 shares Expires 2035-11-12 F1 · derivative.exercise_date: This option was granted on November 13, 2025 as an option for 2,177 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $7.30 per share. The options vest immediately upon grant. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 12:56 UTC | Clene Inc. CLNN · Entity 7166 | Grantstock option · Derivative | 4,278 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001437749-25-027069 · rdgdoc.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,278 Underlying: common stock · 4,278 shares Expires 2035-08-13 F1 · derivative.exercise_date: This option was granted on August 14, 2025 as an option for 4,278 share of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $3.60 per share. The options vest immediately upon grant. Read SEC document |
| June 12, 2025 Filed Jun 27, 2025 20:29 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001826667-25-000091 · wk-form4_1751056186.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 22, 2025 Filed May 23, 2025 19:07 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 6,021 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001562180-25-004127 · primarydocument.xml · derivative · entry 2 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,021 Underlying: Common Stock · 6,021 shares Expires 2035-05-21 F2 · derivative.exercise_date: This option was granted on May 22, 2025 as an option for 6,021 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $2.45 per share. The options vest immediately upon grant. Read SEC document |
| May 22, 2025 Filed May 23, 2025 19:07 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 1,500 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001562180-25-004127 · primarydocument.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option was granted on May 22, 2025 as an option for 1,500 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $2.45 per share. The options vest in 12 equal monthly installments on the 22nd day of each calendar month, beginning June 22, 2025, until such shares are fully vested. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:20 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 3,319 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001562180-25-001804 · primarydocument.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,319 Underlying: Common Stock · 3,319 shares Expires 2035-02-26 F1 · derivative.exercise_date: This option was granted on February 27, 2025 as an option for 3,319 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.42 per share. The options vest immediately upon grant. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 22:40 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | SaleCommon Stock | 30,000 | $3.69 | $110,700.00 |
DisclosureSEC source: 0001415889-24-029160 · form4-12122024_101213.xml · nonDerivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,127 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:18 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 3,280 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001562180-24-008241 · primarydocument.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,280 Underlying: Common Stock · 3,280 shares Expires 2034-12-05 F1 · derivative.exercise_date: This option was granted on December 6, 2024 as an option for 3,280 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.40 per share. The options vest immediately upon grant. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 20:15 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 2,943 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001562180-24-007217 · primarydocument.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,943 Underlying: Common Stock · 2,943 shares Expires 2034-10-01 F1 · derivative.exercise_date: This option was granted on October 2, 2024 as an option for 2,943 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.89 per share. The options vest immediately upon grant. Read SEC document |
| August 13, 2024 Filed Aug 22, 2024 00:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001415889-24-021943 · form4-08222024_120829.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 00:33 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | Disposition to issuerRedeemable Warrants · Derivative | 246,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-019061 · form4-07032024_120751.xml · derivative · entry 2 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 246,667 shares Expires not disclosed F3 · derivative.exercise_price: Represents Warrants received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. F1 · price: As previously disclosed, on May 24, 2024, TriSalus Life Sciences, Inc. (the "Issuer"), announced the commencement of its offer (the "Issuer Tender Offer") to all holders of each class of certain outstanding warrants (the "Warrants"), consisting of (a) the Issuer's publicly-traded Warrants currently listed on the Nasdaq Global Market under the symbol "TLSIW", (b) certain Warrants issued in a private placement transaction occurring simultaneously with the closing of the initial public offering of the Issuer and (c) certain Warrants issued for working capital requirements and payment of certain expenses of the Issuer, each identified in the Prospectus/Offer to Exchange that forms a part of the Issuer's Registration Statement on Form S-4 (Registration No. 333- 279691), filed with the Securities and Exchange Commission on May 24, 2024, to receive 0.3 shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), [continued on footnote 2] F2 · price: [continued from footnote 1] in exchange for each Warrant tendered by the holder and exchanged pursuant to the Issuer Tender Offer. Pursuant to the Issuer Tender Offer, the Reporting Person tendered 246,667 Warrants in exchange for 74,000 shares of Common Stock. F4 · derivative.expiration_date: The Warrants expire on August 9, 2028, or earlier upon redemption or liquidation. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 00:33 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 74,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-019061 · form4-07032024_120751.xml · nonDerivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,127 F1 · price: As previously disclosed, on May 24, 2024, TriSalus Life Sciences, Inc. (the "Issuer"), announced the commencement of its offer (the "Issuer Tender Offer") to all holders of each class of certain outstanding warrants (the "Warrants"), consisting of (a) the Issuer's publicly-traded Warrants currently listed on the Nasdaq Global Market under the symbol "TLSIW", (b) certain Warrants issued in a private placement transaction occurring simultaneously with the closing of the initial public offering of the Issuer and (c) certain Warrants issued for working capital requirements and payment of certain expenses of the Issuer, each identified in the Prospectus/Offer to Exchange that forms a part of the Issuer's Registration Statement on Form S-4 (Registration No. 333- 279691), filed with the Securities and Exchange Commission on May 24, 2024, to receive 0.3 shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), [continued on footnote 2] F2 · price: [continued from footnote 1] in exchange for each Warrant tendered by the holder and exchanged pursuant to the Issuer Tender Offer. Pursuant to the Issuer Tender Offer, the Reporting Person tendered 246,667 Warrants in exchange for 74,000 shares of Common Stock. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:18 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 38,760 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001562180-24-004902 · primarydocument.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,760 Underlying: Common Stock · 38,760 shares Expires 2034-06-06 F1 · derivative.exercise_date: This option was granted on June 7, 2024 as an option for 38,760 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest immediately upon grant. Read SEC document |
| May 29, 2024 Filed May 31, 2024 18:22 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 30,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001562180-24-004533 · primarydocument.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: This option was granted on May 29, 2024 as an option for 30,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest in 12 equal installments of Common Stock on the 29th day of each calendar month, beginning June 29, 2024, until such shares are fully vested. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 20:19 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 33,903 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001562180-24-002590 · primarydocument.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,903 Underlying: Common Stock · 33,903 shares Expires 2034-03-11 F1 · derivative.exercise_date: This option was granted on March 11, 2024 as an option for 33,903 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.44 per share. The options vest immediately upon grant. Read SEC document |
| November 28, 2023 Filed Nov 29, 2023 21:10 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 33,040 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001562180-23-007970 · primarydocument.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,040 Underlying: Common Stock · 33,040 shares Expires 2033-11-28 F1 · derivative.exercise_date: This option was granted on November 28, 2023 as an option for 33,040 shares of Common Stock under the Clene Inc. 2020 Amended Stock Plan at an exercise price of $0.45 per share. The options vest immediately upon grant. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:41 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-23-045685 · doc4.xml · derivative · entry 1 Desai Arjun JJ · CIK 0001982985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.